Retatrutide (Reta) peptide guide

Retatrutide is designed to affect appetite, insulin response, and energy use at the same time. It does this by activating three hormone receptors that normally work in different ways.

The GLP-1 receptor helps reduce appetite and slows stomach emptying. The GIP receptor helps the body respond to insulin after meals. The glucagon receptor is the newer part of the design. In Lilly's preclinical work, glucagon-receptor activity was linked with higher energy use and changes in liver fat metabolism. That is why researchers are studying whether retatrutide can produce larger average weight-loss effects than GLP-1-only drugs.

Most of the human evidence to date comes from Phase 2 trials and one Phase 3 readout. The mechanism details above come from Eli Lilly's preclinical paper in Cell Metabolism (Coskun et al., 2022) and the Phase 1 dose-finding study in Lancet (Urva et al., 2022). These are well-established. The energy-expenditure piece in humans is still being characterized in the ongoing TRIUMPH program.

The strongest single result available as of May 2026 is the TRIUMPH-4 Phase 3 topline, announced by Lilly on December 11, 2025. In 445 adults with obesity and knee osteoarthritis, the highest studied arm produced an average 28.7% body weight loss at 68 weeks (about 71.2 lb / 32.3 kg from a baseline of 112.7 kg). The next-highest studied arm produced 26.4%. Placebo produced 2.1%. The trial also showed a 75.8% reduction in WOMAC knee pain scores in the highest studied arm, with more than one in eight retatrutide-treated patients reporting they were completely free of knee pain by the end. Detailed results are scheduled for a future medical meeting and a peer-reviewed publication.

Before TRIUMPH-4, the most-cited result was the Phase 2 trial in the New England Journal of Medicine (Jastreboff et al., 2023). In 338 adults with obesity, the highest studied arm produced an average 24.2% body weight loss at 48 weeks. Weight loss had not yet plateaued at the end of the trial. A separate Phase 2 trial in Lancet (Rosenstock et al., 2023) tested retatrutide in 281 adults with type 2 diabetes and showed HbA1c reduction plus 16.94% weight loss at 36 weeks in the highest studied arm. A Phase 2a trial in Nature Medicine (Sanyal et al., 2024) showed significant liver fat reduction in patients with metabolic dysfunction-associated steatotic liver disease.

A 2025 systematic review and meta-analysis (Abouelmagd et al., Proceedings of Baylor University Medical Center) pooled three RCTs covering 878 patients. It reported a mean 14.33% body weight reduction across retatrutide study arms versus placebo. Weight loss increased across lower, middle, and higher studied arms in the pooled analysis. I verified these numbers against the open-access PMC publication directly.

Limitations matter. No head-to-head trial has compared retatrutide to tirzepatide or semaglutide in the same patient population. The comparisons published everywhere (including this page) are cross-trial and use different durations and populations. Long-term safety past 68 weeks is unknown. The 4 mg maintenance dose used in some Phase 3 arms has not yet reported. And a new safety signal, dysesthesia, an abnormal touch sensation, appeared in 8.8% of TRIUMPH-4 participants on 9 mg and 20.9% on 12 mg, versus 0.7% on placebo. That signal will need further characterization.

Across the Phase 2 trials and TRIUMPH-4, the most common adverse events were gastrointestinal: nausea, diarrhea, vomiting, and constipation, with frequency rising at higher doses. The 2025 meta-analysis found that adverse-event rates were not significantly different from placebo at 4 mg but were higher at 8 mg and 12 mg. Treatment discontinuation rates in TRIUMPH-4 were broadly similar between retatrutide and placebo arms.

TRIUMPH-4 introduced a new safety observation: dysesthesia, defined as an abnormal sense of touch where ordinary sensations feel unusual or painful. It was reported more often in the higher studied retatrutide arms than placebo. This signal had not appeared at the same magnitude in the Phase 2 program and is being characterized further as additional Phase 3 data reads out. Theoretical class risks for GLP-1 receptor agonists also apply: pancreatitis, gallbladder events, and a contraindication signal for medullary thyroid carcinoma and MEN2 history. Long-term safety past 68 weeks remains uncharacterized.

As of May 2026, retatrutide is not FDA-approved for any use. It is not available by prescription, is not legally compounded by 503A or 503B pharmacies in the United States, and any product sold online as 'retatrutide' or 'reta peptide' for human use is operating outside the FDA framework. Drugs.com states explicitly that under federal law, retatrutide cannot be used in compounded medicines. Lilly has indicated that seven additional Phase 3 readouts are expected through 2026, after which a regulatory submission could follow.